CVMP positive opinion for Vaxxon® ND Clone from Vaxxinova®

Nijmegen, NL / Brescia, IT – Today Vaxxinova® is pleased to announce that the Committee for Medicinal Products for Veterinary Use (CVMP) has adopted a positive opinion, recommending the approval of Vaxxon® ND Clone in the EU.

Vaxxon ND Clone is a vaccine for active immunization of chickens (broilers, future layers and breeders) to reduce mortality and clinical signs of disease caused by infection with Newcastle disease virus.

The final approval by the European Commission is expected before year-end 2024.

Vaxxon ND Clone is the first EU licensed poultry vaccine for Vaxxinova  in the European market.
It marks the introduction of a broader EU licensed poultry vaccine portfolio. Vaxxinova’s licensed and autogenous vaccine solutions are already available in large parts of the world.

About Vaxxinova:

Vaxxinova is a global player in animal vaccines, leveraging decades of expertise in disease
prevention through vaccination. Since 2010, Vaxxinova has combined the knowledge of different companies to become a prominent player in autogenous and registered vaccines.
Our focus is on production animals including poultry, aqua, cattle and swine.
With manufacturing, R&D, and diagnostic facilities in over 10 countries, including the Italian production facilities and The Netherlands R&D, Vaxxinova has established a robust technology network.

Vaxxinova is part of the family-owned EW Group which is based in Germany and operates in the
field of ‘Life Sciences’: genetics, diagnostics, health and nutrition.